The week that Kevin T Conroy took over as CEO of Exact Sciences Corp in  the moleculardiagnostics company got a warning from the Nasdaq that it faced delisting if its market capitalization didnt improve Its efforts to develop a noninvasive test for colon cancer had stalled and its stock was trading at around  Mr Conroy a lawyer who had helmed another companys development of a cervical cancer test rebuilt Exact Sciences from the ground up He joined forces with a Mayo Clinic scientist doing similar research
  